Table 2. Patient and tumour characteristics.

		Premenopausal (n = 13)	Postmenopausal (n = 29a)
Median age (range), y		41 (31-49)	61 (44-81)
IHC ER, n	ER+	7	20
	ER-	6	9
IHC PR, n	PR+	7	17
	PR-	6	12
MLPA, EGFR/HER1, n	Ampl*	0	1
	Non-ampl	13	25
MLPA, HER2, n	Amplb	5	4
	Non-ampl	8	22

Abbreviations: IHC, Immunohistochemistry; ER, estrogen receptor; PR, progesterone receptor

^a Normal tissue was not available for MLPA and mRNA analyses from one patient and tumour tissues were not available from two other patients

^b More than 2 alleles of either HER2 or EGFR were considered amplified.